Apogee Tx's corporate presentation
Project goal
We developed a flexible presentation template that served as the foundation for multiple decks tailored to different company needs, including event-specific presentations and a core corporate overview. Our objective was to design clear slides that translated Apogee’s biologic pipeline, clinical trial data, and long-acting dosing profiles in inflammatory and immunological diseases into a cohesive and confident framework. Across these efforts, we focused on clarifying complex trial designs, cross-study data, and long-term market opportunity for investors and partners while preserving scientific rigor, ultimately producing more than 150 slides.
Deck Highlights
APG279 co-formulation: molecular design and biomarker impact
Associate Director, BD & Strategy
The Process
Project timline:
7 weeks
Review:
2 zoom call + 5 e-mail feedback sessions
Find out which of our 26 scientific animation options works best for investor relations and communications:
Our design process was grounded in close collaboration with Apogee’s scientific and investor relations teams, as the scope extended beyond presenting the science alone. Apogee required decks across extensive clinical data, market analysis, and strategic positioning, and our role was to unify this information into a cohesive deck presentation system suitable for board and investor audiences.
We translated complex trial designs, biomarker data, and cross-study efficacy comparisons into a clear presentation using precise 2D data visualization and custom 3D antibody modeling. The deck includes standardized longitudinal efficacy charts, dosing interval and injection frequency visuals, pipeline and milestone timelines, and MoA graphics illustrating IL-13 inhibition and combination strategies.
Schematic and detailed 3D antibody visuals supported discussions of molecular design and differentiation. Developing a color-coding framework for numerous programs—while remaining within Apogee’s established visual identity—was a key challenge. All visuals were aligned with molecular animations we created for Apogee, ensuring consistency across static and animated scientific communication for biotech audiences.
Outcome
The final corporate overview positioned Apogee as a differentiated biotechnology company across a broad range of inflammatory and immunological diseases. By clearly presenting clinical progress, long-acting dosing profiles, and pipeline strategy across programs, the deck reinforced Apogee’s scientific and strategic differentiation. The presentation supports key 2026 milestones, including Phase 2 readouts and planned Phase 3 initiation, while providing a strong foundation for investor engagement as Apogee advances towards a 2029 launch.
